Kiromic Biopharma

Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. Its platform, DIAMOND AI, discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The company is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiromic Biopharma, Inc. is a clinical stage biotherapeutics company, which engages in DIAMOND AI and discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The firm is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about July 2, 2021 (the “IPO”); and/or (ii) between June 25, 2021 and August 13, 2021, both dates inclusive (the “Class Period”). If you wish to ser

EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

SAN DIEGO--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Biopharma, Inc. (KRBP) failed to disclose the FDA had placed a clinical hold on two of its drug candidates

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) in the United States district Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Kiromic securities between June 25, 2021 and August 13, 2021, both dates inclusive, or pursuant to the Compan

KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company's Vice President of Research & Development and

Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer

Kiromic BioPharma Inc (NASDAQ: KRBP) has completed the construction of its expanded current good manufacturing practice manufacturing facility in Houston. The expanded facility located at Kiromic's headquarters is one of the conditions required for the Company to begin.

Why Kiromic BioPharma Shares Are Trading Higher Today?

Adverum Biotechnologies

American Rebel Holdings Inc

Top penny stocks to watch this week. The post Top Penny Stocks To Buy Today?

Top Penny Stocks To Buy Today? 3 To Watch Under $3

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the timely completion of construction on its expanded current good manufacturing practice (cGMP) manufacturing facility in Houston. This significant milestone was accomplished within the t

Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline

Kiromic BioPharma Inc (NASDAQ: KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT. Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022.

Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and data mining platform to discover and develop cell therapies with a focus on immuno-oncology, announces a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT™. Kiromic expects to submit its first new investigational new drug (IND) application to the U.S. Food an

Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate

Bionomics Ltd

Esports Entertainment Group

Lesaka Technologies Inc

PureCycle Technologies

PMV Pharmaceuticals

Entrada Therapeutics

Vigil Neuroscience

We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.

Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday

Kiromic BioPharma (KRBP) stock is rocketing higher on Tuesday following announcing a new sponsored research agreement (SRA). The post Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today?

Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today?

Kiromic Biopharma Inc (NASDAQ: KRBP) shares are trading higher by 78.5% at $0.50 after the company entered a Sponsored Research Agreement (SRA) under which in vivo preclinical data will be generated from Kiromic's Gamma Delta T cell allogeneic therapies. "We believe that the SRA will.

Why Kiromic Biopharma Shares Are Skyrocketing Today

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces financial results for the first quarter ended March 31, 2022. “This past quarter has seen tremendous progress inside the Company, particularly within th

Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the Company will submit an amended Investigational New Drug Application (IND) for its first oncology cell therapy candidate Procel™ directly to the FDA

Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Evoke Pharma

Globalstar

IT Tech Packaging Inc

Kala Pharmaceuticals

MEI Pharma

Pingtan Marine Enterprise

PolarityTE Inc

Sesen Bio Inc.

Sonim Technologies Inc

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Company's most recent corporate presentation. The updated presentation can be accessed on the investor relations s

Kiromic BioPharma Announces Availability of Company's Current Corporate Presentation

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces financial results for the fourth quarter and fiscal year ended December 31, 2021. “We are extremely encouraged by the progress the Company demonstra

Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces that it has filed a Form 12b-25 with the SEC to obtain a 15-calendar day extension to file its Annual Report on Form 10-K for the

Kiromic Biopharma Announces Filing of Form 12b-25

San Francisco, California--(Newsfile Corp. - March 31, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. The firm is investigating Kiromic's possible securities law violations.Visit: https://www.hbsslaw.com/investor-fraud/KRBPContact An Attorney Now: KRBP@hbsslaw.com844-916-0895Kiromic BioPharma, Inc. (KRBP) Investigation: The investigation focuses on Kiromic's disclosures about its development of two cancer treatment product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1. In

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma, Inc. (KRBP) Investors to Investigation of Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's Attorneys

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results

Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results

Guardion Health Sciences Inc

Powerbridge Technologies Co Ltd

Exicure Inc

Penny stocks to watch under $1 this week. The post 4 Top Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Buy For Under $1 This Week

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Announces Changes in Management, Board of Directors

Kiromic BioPharma Announces Changes in Management, Board of Directors

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company's Board of Directors

Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company's Board of Directors

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

News for Kiromic Biopharma Stock (KRBP)